ArticleBiophotonics discovery2025
Structured light imaging mesoscopy: application to skin changes in scleroderma.
Article in Biophotonics discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structured light imaging mesoscopy: detection of embedded morphological changes in superficial tissues.Journal of biomedical optics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: Scleroderma is a chronic, autoimmune disorder, characterized by the fibrosis of skin and internal organs. The extent of skin fibrosis is a good predictor of disease severity and mortality. Structured light imaging mesoscopy (SLIM) is a noncontact and label-free imaging technique that requires minimal postprocessing and no inverse model. SLIM may provide improved disease diagnosis and monitoring of scleroderma. Aim: We aim to evaluate SLIM as a new optical method to assess skin involvement in scleroderma. Approach: SLIM measurements were collected from 25 scleroderma patients and 18 healthy controls across a range of spatial frequencies and wavelengths to find the optimal imaging parameters across skin tones. Monte Carlo simulations were conducted on a multilayer skin model that mimicked known biological changes in scleroderma. Results: Clinical data and simulations show that optimal spatial frequency ( Conclusions: SLIM can be used as a quantitative and objective method to assess skin involvement in scleroderma. The optimal imaging parameters target the relevant depths of the skin, making it sensitive to biological changes in scleroderma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.